Patients without ovarian cancer were excluded from retrospective analysis of details of hypersensitivity reactions recorded contemperaneously between April 2019 - January 2020 on excel and chemocare (CIS Oncology, Belfast, UK) by the treating practitioner. Cancer. LUGANO-MADRID, 09 September, 2017 -The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for . Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. Oncol Res Treat. The PAGA project aims to adapt the ESMO Clinical Practice Guidelines by integrating Asian ethnic, scientific, socioeconomic, and local practice characteristics. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. (Bruchim et al., 2014) demonstrated safe re-treatment with carboplatin using a desensitization protocol to reduce repeated hypersensitivity reactions, and Koshiba et al. Careers. Thus, the risk of severe carboplatin-related hypersensitivity may influence its usage in gynecological cancers, and it is important to develop protocols to reduce this risk, especially the risk of severe reactions. We further evaluated the median carboplatin cycle and dose administered to women with and without carboplatin-related hypersensitivity. The https:// ensures that you are connecting to the Monitor. (2013). Fu. Patients who previously received platinum compounds were excluded. Parmar et al. (2010). European Hematology Association (EHA) and European . (PDF) Management of cancer pain in adult patients: ESMO Clinical The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. Reducing the carboplatin infusion rate and employing desensitization protocols with anti-allergy medications are especially important for patients at high risk of carboplatin hypersensitivity to detect the hypersensitivity early and avoid severe hypersensitivity without compromising the efficacy of the antineoplastic regimen. The drug or food allergy in 735 patients receiving carboplatin-based chemotherapy. We analyzed the relationships among the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions in this patient population. The incidence of severe carboplatin-related hypersensitivity reactions ranges from 2 to 6%, with the lowest incidence occurring in our study. Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma. (2006). A Comprehensive Methodology to Systematically Identify Drug - Springer This study was approved by the Research Ethics Committee at the National Taiwan University Hospital (201706023RINC). Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? eCollection 2017. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). *Correspondence: Wen-Fang Cheng, wenfangcheng@yahoo.com, Creative Commons Attribution License (CC BY). Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. Oncology 61, 129133. The symptoms and signs of the 75 women with carboplatin-related hypersensitivity reactions are given in Table 4. The cumulative incidence of carboplatin-related hypersensitivity was 2% at >3,500 mg, 6% at >7,500 mg, 8% at >10,000 mg, and 10% at >16,000 mg with a plateau beyond this dose (Figure 1B).
Share this article